Objective Diagnostic Markers and Personalized Intervention in MDD Patients

Conditions

Depressive Disorder, Major

Brief summary

Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high recurrence rate, suicide rate and disability rate. It's reported that the global burden caused by MDD will be up to the second rank among all the disease burdens by 2020. China is also confronted with the daunting challenges against MDD. It's assessed that the monthly incidence of MDD is 6.1%, non-hospitalizing rate reaches up to 92% and the non-treatment rate is approximate 95%. However, to date, the pathogenesis of MDD is obscure and the current therapies don't work well. Therefore, it's urgent and critical to elucidate the pathogenesis of MDD, to develop early diagnostic criteria and effective intervention in MDD. Considering the diversity of weights on genetic factor and environmental factor in MDD, in this project, the investigators aim firstly to explore the effect of genetic-environmental interactionon the pathogeny of MDD for classifying MDD into genetic type, environmental type and others based on a case-control study. We next conduct the neurobiological, neurocognitive and psycho-behavioral assessments among MDD, schizophrenia and healthy groups to screen the salient endophenotypes for establishing the diagnostic models of MDD . The investigators further analyse the changes of these indicators after 8 weeks'medication to select the potential predictors for therapeutic evaluations and interventional options in MDD patients. Finally, the investigators continue a 2-year follow-up study to test and verify the predictors of prognosis in MDD patients.

Li-Min Xin, Jingyu Lin, Hongzhen Fan, FengYan, Xin Yu et al. (7 authors)

BMC Psychiatry2026-04-11

10.1186/s12888-026-08043-8

Effect of childhood trauma on cognitive function in individuals with major depressive disorder and healthy controls.

Cui F, Liu Q, Lv X, Tian H, Wei J, Zhang K, Zhu G, Chen Q, Wang G, Wang X, Zhang N, Huang Y, Si T, Yu X.

2024-10-191 citations

10.1016/j.jad.2024.10.059

Proinflammatory phenotype in major depressive disorder with adulthood adversity: In line with social signal transduction theory of depression.

Lin J, Li JT, Kong L, Liu Q, Lv X, Wang G, Wei J, Zhu G, Chen Q, Tian H, Zhang K, Wang X, Zhang N, Yu X, Si T, Su YA.

2023-08-307 citations

10.1016/j.jad.2023.08.104

Childhood adversity, adulthood adversity and suicidal ideation in Chinese patients with major depressive disorder: in line with stress sensitization.

Lin J, Su Y, Lv X, Liu Q, Wang G, Wei J, Zhu G, Chen Q, Tian H, Zhang K, Wang X, Zhang N, Yan H, Wang Y, Yu X, Si T.

2022-01-0512 citations

10.1007/s00406-021-01375-4

Severe sleep disturbance is associated with executive function impairment in patients with first-episode, treatment-naïve major depressive disorders

Feihuan Cui, Qi Liu, Xiaozhen Lv, Rainer Leonhart, Hongjun Tian et al. (15 authors)

BMC Psychiatry2021-04-197 citations

10.1186/s12888-021-03194-2

Association between Perceived Stressfulness of Stressful Life Events and the Suicidal Risk in Chinese Patients with Major Depressive Disorder

Jingyu Lin, Yu Huang, Yun‐Ai Su, Xin Yu, Xiaozhen Lyu et al. (7 authors)

Chinese Medical Journal2018-04-1136 citations

10.4103/0366-6999.229898

The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.

Lv X, Si T, Wang G, Wang H, Liu Q, Hu C, Wang J, Su Y, Huang Y, Jiang H, Yu X.

2016-07-1525 citations

10.1186/s12888-016-0953-z

Interventions

DRUGSSRIs

fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. For MDD group: Inclusion criteria: * Age between 18-55, male or female; * The diagnosis of MDD consistent with DSM-IV (M.I.N.I) * First-episode or relapsed; * Certain ability of reading and writing to complete the questionnaire survey and psychological assessment. * All participants provide written confirmation of informed consent prior to engaging the study protocol.

Exclusion criteria

* Current psychopathology or a history of neurologic conditions, including alcohol/substances dependence, the diagnosis of cognition impairment; * Severe somatic diseases, such as severe cardio-cerebral vascular diseases, respiratory diseases, liver diseases, kidney diseases, or malignant tumors; * Not signed the informed consent; * Been engaging other studies. 2. For Healthy control group Inclusion criteria: * age between 18 and 55 years at the time of enrollment; * providing written confirmation of informed consent prior to engaging the study.

Design outcomes

Primary

Measure	Time frame	Description
The changes of HAMD total score at 8 weeks from baseline	week 0,2,4,8	The scores are assessed at 0,2,4,8 weeks since the medication begins for MDD group

Secondary

Measure	Time frame	Description
The changes of HAMA total score at 8 weeks from baseline	week 0,2,4,8	The scores are assessment at 0,2,4,8 weeks since the medication begins for MDD group
The change of CGI score at 8 weeks from baseline	week 0,2,4,8	The scores are assessment at 0,2,4,8 weeks since the medication begins for MDD group
The prognosis after the intervention	Up to 2 years	—
Number of participants with serious and non-serious adverse events	Up to two years	—

Countries

China

Contacts

Primary ContactTianmei Si, MD

si.tian-mei@163.com86-10-62723748

Backup ContactGang Wang, MD

gangwangdoc@mail1.bbuser.com

Outcome results

None listed